+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A phase II open-label, randomized study of the triple combination of Indinavir, zidovudine and didanosine versus Indinavir alone and zidovudine/didanosine in antiretroviral naive patients



A phase II open-label, randomized study of the triple combination of Indinavir, zidovudine and didanosine versus Indinavir alone and zidovudine/didanosine in antiretroviral naive patients



INFECTIOUS DISEASES SOCIETY OF AMERICA Author, NATIONAL INSTITUTES OF HEALTH Author, CENTERS FOR DISEASE CONTROL and PREVENTION Author 3rd Conference on retroviruses and opportunistic infections : 90




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 029743420

Download citation: RISBibTeXText


Related references

A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients. Journal of Acquired Immune Deficiency Syndromes 27(2): 116-123, 2001

Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients. Aids 14(16): 2567-2574, 2000

A open-label, randomized, comparative study of stavudine + didanosine + indinavir versus d4T + ddI + nevirapine in treatment of HIV-infected naive patients. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 40: 280, 2000

Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014). Current Medical Research and Opinion 20(7): 1103-1114, 2004

A phase III, multicenter, randomized, open label study to compare the antiretroviral activity and tolerability of efavirenz plus indinavir , versus EFV plus zidovudine plus lamivudine , versus IDV plus ZDV plus 3TC at 36 weeks. AIDS 12(Suppl. 4): S13, 1998

A phase II, multi-center randomized, open label study to compare the antiretroviral activity and tolerability of efavirenz + indinavir , versus EFV + zidovudine +lamivudine , versus IDV + 3TC at 36 weeks. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 38: 394, 1998

AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients. Aids 14(4): 367-374, 2000

Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviraltherapy-naive HIV-infected individuals with CD4 cell counts between 50 and 250/mm3. Revista do Instituto de Medicina Tropical de Sao Paulo 42(1): 27-36, 2000

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II). Aids 14(11): 1601-1610, 2000

A Comparative Study of a Combination of Zidovudine, Didanosine and Double Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine. AMERICAN SOCIETY FOR MICROBIOLOGY Author Human retroviruses and related infections : 125, 1995

Abacavir, Didanosine and Stavudine versus Ritonavir, Saquinavir, Zidovudine and Lamivudine or Nelfinavir, Nevirapine, Zidovudine and Lamivudine in antiretroviral naive HIV patients. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 42: 261, 2002

A pilot, multicenter, open-label, randomized study to compare the safety and activity of indinavir sulfate administered every 8 hours versus every 12 h in combination with zidovudine and lamivudine. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 37: 260, 1997

An open-label, randomized, comparative study of stavudine + lamivudine + indinavir versus zidovudine + 3TC + IDV in treatment of HIV-infected patients START I. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 39: 471, 1999

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial. JAMA 285(9): 1155-1163, 2001

Suppression of maternal virus load with zidovudine, didanosine, and indinavir combination therapy prevents mother-to-fetus HIV transmission in macaques. Journal of Acquired Immune Deficiency Syndromes 25(2): 140-149, 2000